September 26, 2024 09:00 PM EDT
Startups
Special

End­points 11 win­ner As­cid­i­an Ther­a­peu­tics: A search-and-re­place tech­nol­o­gy comes to RNA

Ryan Cross

Senior Science Correspondent

↑
  • CEO Michael Ehlers
  • To­tal raised $90 mil­lion
  • Head­quar­ters Boston, MA

As­cid­i­an Ther­a­peu­tics has a se­cret list of near­ly 400 dis­eases …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

J&J and Bay­er to lay off al­most 300 staffers in New Jer­sey

23andMe CEO says she is no longer open to out­side takeover of­fers

Ron Re­naud's new obe­si­ty biotech, Kail­era, has $400M to go straight to Phase 3

GSK’s Vi­iV stops de­vel­op­ment of Phase 2 HIV an­tivi­ral

Judge keeps Am­gen's $10.7B tax li­a­bil­i­ty suit alive 

sponsored

3 Tiers for AAV Po­ten­cy As­say De­vel­op­ment Suc­cess

A service from the Financial Times